• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

    11/13/24 4:27:48 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MLYS alert in real time by email
    SC 13G/A 1 d913151dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Mineralys Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    603170101

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 603170101    13G

     

     1.   

     NAMES OF REPORTING PERSONS

     

     TCG Crossover GP II, LLC

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     2,470,265 (1)

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     2,470,265 (1)

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,470,265 (1)

    10.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.0% (2)

    12.  

     TYPE OF REPORTING PERSON (see instructions)

     

     OO

     

    (1)

    Consists of 2,470,265 shares of Common Stock (as defined in Item 2(d) below) of the Issuer (as defined in Item 1(a) below) held of record by TCG Crossover II (as defined in Item 2(a) below). TCG Crossover GP II (as defined in Item 2(a) below) is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Represents an ownership interest of 4.97%, based on 49,726,675 shares of Common Stock outstanding as of August 2, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “Commission”) on August 13, 2024 (the “Form 10-Q”).


    CUSIP No. 603170101    13G

     

     1.   

     NAMES OF REPORTING PERSONS

     

     TCG Crossover Fund II, L.P.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     2,470,265 (1)

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     2,470,265 (1)

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,470,265 (1)

    10.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.0% (2)

    12.  

     TYPE OF REPORTING PERSON (see instructions)

     

     PN

     

    (1)

    Consists of 2,470,265 shares of Common Stock of the Issuer held of record by TCG Crossover II. TCG Crossover GP II is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Represents an ownership interest of 4.97%, based on 49,726,675 shares of Common Stock outstanding, as reported by the Issuer in the Form 10-Q.


    CUSIP No. 603170101    13G

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Chen Yu

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     2,470,265 (1)

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     2,470,265 (1)

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,470,265 (1)

    10.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.0% (2)

    12.  

     TYPE OF REPORTING PERSON (see instructions)

     

     IN

     

    (1)

    Consists of 2,470,265 shares of Common Stock of the Issuer held of record by TCG Crossover II. TCG Crossover GP II is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Represents an ownership interest of 4.97%, based on 49,726,675 shares of Common Stock outstanding, as reported by the Issuer in the Form 10-Q.


    CUSIP No. 603170101    13G

    Explanatory Note

    This Amendment No. 1 (“Amendment No. 1”) amends and supplements the Schedule 13G initially filed with the Commission on February 15, 2024 (the “Original Schedule 13G”) and is being filed by TCG Crossover Fund II, L.P. (“TCG Crossover II”) and TCG Crossover GP II, LLC (“TCG Crossover GP II” and together with TCG Crossover II, the “Reporting Entities”) and Chen Yu (the “Reporting Individual”). The Reporting Entities and the Reporting Individual are collectively referred to as the “Reporting Persons.” The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is filed as Exhibit 1 to the Original Schedule 13G. Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 1 have the meanings ascribed to them in the Original Schedule 13G.

     

    Item 4.

    Ownership.

     

      (a)

    Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (b)

    Percent of class:

    See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote

    See Row 5 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (ii)

    Shared power to vote or to direct the vote

    See Row 6 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (iii)

    Sole power to dispose or to direct the disposition of

    See Row 7 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (iv)

    Shared power to dispose or to direct the disposition of

    See Row 8 of the cover page for each Reporting Person and the corresponding footnotes.*

     

    *

    Except to the extent of his or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than 5% of the class of securities, check the following: ☒


    CUSIP No. 603170101    13G

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 13, 2024

     

    TCG Crossover Fund II, L.P.
    By:   TCG Crossover GP II, LLC
    Its:   General Partner
    By:   /s/ Craig Skaling
      Authorized Signatory
    TCG Crossover GP II, LLC
    By:   /s/ Craig Skaling
      Authorized Signatory
    /s/ Craig Skaling, as attorney-in-fact for Chen Yu
    Chen Yu
    Get the next $MLYS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MLYS

    DatePrice TargetRatingAnalyst
    7/10/2024$30.00Buy
    H.C. Wainwright
    4/2/2024$30.00Buy
    Goldman
    3/7/2023Outperform
    Evercore ISI
    3/7/2023$39.00Buy
    BofA Securities
    3/7/2023$32.00Buy
    Guggenheim
    3/7/2023$27.00Overweight
    Wells Fargo
    3/7/2023$45.00Buy
    Stifel
    3/7/2023$40.00Outperform
    Credit Suisse
    More analyst ratings

    $MLYS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      – Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 2025 – – Initiated Explore-OSA Phase 2 Trial in Q1 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced financial results for

      5/12/25 4:05:00 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

      RADNOR, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Bank of America Securities 2025 Health Care Conference being held in Las Vegas on May 12-15, 2025. Bank of America Securities Health Care ConferenceDate: Wednesday, May 14, 2025Time: 4:35pm PDTFormat: PresentationWebcast Link    A live webcast of the presentation can be accessed under "News and Events" on the Investor Relations s

      5/7/25 8:00:00 AM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

      RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2025, after the financial markets close on Monday, May 12, 2025. Monday, May 12th @ 4:30 p.m. ET Domestic:1-800-717-1738International:1-646-307-1865Conference ID:53214Webcast:Link   A live webcast of the conference call may also be found on the "News & Events" page in the Investor Relations section of

      5/5/25 4:05:00 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLYS
    SEC Filings

    See more
    • SEC Form 144 filed by Mineralys Therapeutics Inc.

      144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)

      5/14/25 4:24:50 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Mineralys Therapeutics Inc.

      10-Q - Mineralys Therapeutics, Inc. (0001933414) (Filer)

      5/12/25 5:31:11 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mineralys Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)

      5/12/25 4:13:55 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLYS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Rodman David Malcom sold $173,774 worth of shares (11,366 units at $15.29), decreasing direct ownership by 10% to 106,669 units (SEC Form 4)

      4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

      5/15/25 7:01:41 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Rodman David Malcom exercised 6,349 shares at a strike of $1.08, increasing direct ownership by 6% to 118,035 units (SEC Form 4)

      4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

      5/13/25 8:57:09 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Slingsby Brian Taylor bought $3,499,996 worth of shares (259,259 units at $13.50) (SEC Form 4)

      4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

      4/25/25 7:01:59 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLYS
    Financials

    Live finance-specific insights

    See more
    • Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      – Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 2025 – – Initiated Explore-OSA Phase 2 Trial in Q1 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced financial results for

      5/12/25 4:05:00 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

      RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2025, after the financial markets close on Monday, May 12, 2025. Monday, May 12th @ 4:30 p.m. ET Domestic:1-800-717-1738International:1-646-307-1865Conference ID:53214Webcast:Link   A live webcast of the conference call may also be found on the "News & Events" page in the Investor Relations section of

      5/5/25 4:05:00 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

      – Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile – – Lorundrostat is a highly selective aldosterone synthase inhibitor that disrupts aldosterone biosynthesis rather than blocking the mineralocorticoid receptor – – Data from Advance-HTN support the potential of lorundrostat as a best-in-class treatment for high-risk patients with uncontrolled or resistant hypertension who would normally be treated in a specialist setting – RADNOR, Pa., March 29, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmace

      3/29/25 2:30:00 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLYS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Mineralys Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00

      7/10/24 7:50:59 AM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Mineralys Therapeutics with a new price target

      Goldman initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00

      4/2/24 7:34:24 AM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evercore ISI initiated coverage on Mineralys Therapeutics

      Evercore ISI initiated coverage of Mineralys Therapeutics with a rating of Outperform

      3/7/23 7:43:03 AM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLYS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Slingsby Brian Taylor bought $3,499,996 worth of shares (259,259 units at $13.50) (SEC Form 4)

      4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

      4/25/25 7:01:59 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Samsara Biocapital Gp, Llc bought $8,100,000 worth of shares (600,000 units at $13.50) (SEC Form 4)

      4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

      3/17/25 9:05:47 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Akkaraju Srinivas bought $8,100,000 worth of shares (600,000 units at $13.50) (SEC Form 4)

      4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

      3/17/25 9:04:15 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLYS
    Leadership Updates

    Live Leadership Updates

    See more
    • Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer

      RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointment of Minji Kim, Ph.D. as Chief Business Officer. Adam Levy will remain in his role as Chief Financial Officer. "With our expanding operations, we have decided to split the functions of Chief Financial Officer and Chief Business Officer into two roles, and we are excited to have Minji join our team. She brings a solid track record of generating value for multiple companies by identify

      1/4/24 4:05:00 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy

      LOS ANGELES, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Praxis Bioresearch ("Praxis"), a biopharmaceutical company focused on the discovery and development of therapeutics for chronic neuropsychiatric and neurodegenerative disorders with an initial focus on apathy in Alzheimer's Disease, today announced the appointment of Adam Levy to its Board of Directors (the "Board"). Mr. Levy brings executive, financial and operational leadership experience in biopharmaceuticals. "We are excited to have Adam join our Board and support our mission to improve the lives of patients with Alzheimer's Disease," said Sandeep Patil, MD PhD, chief executive officer of Praxis Bioresearch. "Adam brings an impressive

      9/19/23 4:00:00 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLYS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

      SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

      11/13/24 4:27:48 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

      SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

      11/13/24 4:19:46 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

      SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

      11/13/24 4:09:56 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care